Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Company Performance - Gilead Sciences (GILD) closed at $89.14, reflecting a -1.64% change from the previous day's closing price, underperforming the S&P 500 which gained 0.16% [1] - Over the past month, Gilead's shares have decreased by 3.51%, which is better than the Medical sector's decline of 5.31% and the S&P 500's loss of 2.7% [2] - The upcoming earnings report is scheduled for February 11, 2025, with an expected EPS of$ 1.67, indicating a 2.91% decline year-over-year, and a revenue forecast of $7.05 billion, down 0.88% from the previous year [3] Analyst Estimates - Recent changes in analyst estimates for Gilead Sciences reflect evolving short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] - The Zacks Consensus EPS estimate has increased by 2.15% in the past month, and Gilead currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 11.81, which is lower than the industry average Forward P/E of 22.58, indicating a valuation discount [7] - The company has a PEG ratio of 1.26, compared to the industry average PEG ratio of 1.5, suggesting a favorable growth outlook relative to its valuation [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead, has a Zacks Industry Rank of 64, placing it in the top 26% of over 250 industries, indicating strong relative performance [9]